Drugs: Pembrolizumab
Pembrolizumab Label Expansion: KEYNOTE-826 Trial Insights on Advanced Cervical Cancer
The KEYNOTE-826 trial reveals critical insights into pembrolizumab's effectiveness in treating advanced cervical cancer, expanding its therapeutic potential.
Intelligence Snapshot
Executive Summary
Main news: The U.S. Food and Drug Administration (FDA) approved Pembrolizumab (Keytruda) on October 13, 2021, for the first-line treatment of specific advanced cervical cancer. This FDA pembrolizumab approval was based on the KEYNOTE-826 trial.
Key Insights
-
Clinical impact: The KEYNOTE-826 trial demonstrated significant improvements in…
Clinical impact: The KEYNOTE-826 trial demonstrated significant improvements in progression-free survival (PFS) and overall survival (OS) when pembrolizumab was combined with chemotherapy, with or without bevacizumab.
-
Market implications: This approval expands treatment options for patients with…
Market implications: This approval expands treatment options for patients with PD-L1-positive (CPS ≥1) persistent, recurrent, or metastatic cervical cancer, potentially shifting the standard of care.
-
Next steps: Further studies may explore pembrolizumab's effectiveness in earlier stages…
Next steps: Further studies may explore pembrolizumab's effectiveness in earlier stages of cervical cancer and in combination with other novel agents.
Market Impact
| Regulatory | medium |
|---|---|
| Commercial | medium |
| Competitive | low |
| Investment | low |
Loading intelligence…
Quick Answer
Key Questions
- What is the significance of the KEYNOTE-826 trial?
- Who is the ideal candidate for Pembrolizumab treatment for cervical cancer?
- When did the Pembrolizumab FDA approval occur?
Executive Scorecard
Heuristic scores · directional, not investment adviceRegulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for Pembrolizumab.
Unlock full calendar →Investor brief
Download a one-page summary of regulatory impact and competitive context.
Explore drug hub →Contents11 sections
Medically Reviewed
by Dr. James Morrison, Chief Medical Officer (MD, FACP, FACC)
Reviewed on: April 26, 2026
Key Takeaways
- Main news: The U.S. Food and Drug Administration (FDA) approved Pembrolizumab (Keytruda) on October 13, 2021, for the first-line treatment of specific advanced cervical cancer. This FDA pembrolizumab approval was based on the KEYNOTE-826 trial.
- Clinical impact: The KEYNOTE-826 trial demonstrated significant improvements in progression-free survival (PFS) and overall survival (OS) when pembrolizumab was combined with chemotherapy, with or without bevacizumab.
- Market implications: This approval expands treatment options for patients with PD-L1-positive (CPS ≥1) persistent, recurrent, or metastatic cervical cancer, potentially shifting the standard of care.
- Next steps: Further studies may explore pembrolizumab's effectiveness in earlier stages of cervical cancer and in combination with other novel agents.
On October 13, 2021, the Pembrolizumab (Keytruda) received Pembrolizumab FDA approval for the first-line treatment of persistent, recurrent, or metastatic cervical cancer in patients with PD-L1-positive tumors (CPS ≥1). [Source: U.S. Food and Drug Administration] This Pembrolizumab FDA approval was based on the phase 3 KEYNOTE-826 trial, which demonstrated significant progression-free survival (PFS) and overall survival (OS) benefits when combined with chemotherapy with or without bevacizumab. Why it matters: This approval provides a new first-line treatment option that significantly improves outcomes in PD-L1-positive advanced cervical cancer.
FDA are the agencies to watch. Regulatory relevance reads medium for oncology, with Pembrolizumab most exposed to upcoming decisions. Teams should track submission types, designations, and guidance shifts that could move approval timelines.IntelligenceRegulatory Impact
Drug Overview
Pembrolizumab (Keytruda) is a monoclonal antibody that functions as a PD-1 immune checkpoint inhibitor. It is approved for the first-line treatment of persistent, recurrent, or metastatic cervical cancer in patients with PD-L1-positive tumors (CPS ≥1).
IntelligenceCompetitive Intelligence
Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.
Clinical Insights
The Pembrolizumab FDA approval was supported by the KEYNOTE-826 trial (NCT03635567), a phase 3, randomized, double-blind study. The trial evaluated Pembrolizumab plus chemotherapy with or without bevacizumab versus placebo plus chemotherapy with or without bevacizumab.
The primary endpoints of KEYNOTE-826 were progression-free survival (PFS) and overall survival (OS) in patients with PD-L1-positive tumors (CPS ≥1). Pembrolizumab in combination with chemotherapy, with or without bevacizumab, demonstrated significant PFS and OS benefits in this patient population. Compared with prior standard of care, the addition of pembrolizumab has shifted treatment paradigms. The safety profile was consistent with known pembrolizumab toxicities.
IntelligenceMarket Signals
Commercial pull is medium and investment relevance low. Expect implications for oncology pricing, access, and launch sequencing.
Regulatory Context
The Pembrolizumab FDA approval for this indication was granted on October 13, 2021, based on the results of the KEYNOTE-826 trial.
IntelligenceStrategic Takeaways
Main news: The U.S. Food and Drug Administration (FDA) approved Pembrolizumab (Keytruda) on October 13, 2021, for the first-line treatment of specific advanced cervical cancer. This FDA pembrolizumab approval was based on the KEYNOTE-826 trial. Clinical impact: The KEYNOTE-826 trial demonstrated significant improvements in progression-free survival (PFS) and overall survival (OS) when pembrolizumab was combined with chemotherapy, with or without bevacizumab. Market implications: This approval expands treatment options for patients with PD-L1-positive (CPS ≥1) persistent, recurrent, or metastatic cervical cancer, potentially shifting the standard of care.
Market Impact
This Pembrolizumab FDA approval strengthens its market position in the treatment of advanced cervical cancer. The expanded label is expected to increase Pembrolizumab adoption, particularly for patients with PD-L1-positive tumors. The approval introduces immuno-oncology benefits in a market where competitive drugs include bevacizumab and chemotherapy regimens without immunotherapy. This differentiates Pembrolizumab by demonstrating statistically significant survival benefits when combined with chemotherapy, with or without bevacizumab, in PD-L1-positive advanced cervical cancer patients.
IntelligenceEvidence Quality
Claims are grounded in the cited primary and secondary sources, with editorial review applied before publication.
Future Outlook
The success of Pembrolizumab in KEYNOTE-826 paves the way for further exploration of immunotherapy combinations in cervical cancer and other Gynecologic Oncology indications. What to watch next: Ongoing trials may investigate Pembrolizumab in earlier disease stages or in combination with novel agents.
Frequently Asked Questions
What is the significance of the KEYNOTE-826 trial?
The KEYNOTE-826 trial demonstrated that Pembrolizumab, when combined with chemotherapy with or without bevacizumab, significantly improved progression-free survival (PFS) and overall survival (OS) in patients with PD-L1-positive advanced cervical cancer.
Who is the ideal candidate for Pembrolizumab treatment for cervical cancer?
The ideal candidate is a patient with persistent, recurrent, or metastatic cervical cancer whose tumors are PD-L1-positive, defined by a CPS ≥1.
When did the Pembrolizumab FDA approval occur?
The Pembrolizumab FDA approval was granted on October 13, 2021.
References
References
- U.S. Food and Drug Administration. FDA approval. Accessed 2026-04-26.
Related profiles
Related coverage
Continue Exploring
Jump into the entities behind this story.
Ask AI About Oncology
Grounded in NovaPharmaNews intelligence. Pick a prompt to start.
Follow Pembrolizumab developments
FDA oncology alerts and Pembrolizumab pipeline updates, every Monday.
- Evidence strength
- 71/100
- Last verified
- Jun 14, 2026
- AI-assisted review
- Yes
- Editorial review
- Dr. Sarah Chen
Moderate source quality · grounded in cited primary and secondary sources.
This article follows our editorial standards. Report a correction via editorial contact.
About the Author
Continue Your Research
Industry Reports & Whitepapers
- La Negoziazione del Prezzo dei Farmaci Oncologici in Italia — This whitepaper analyzes the market benchmark role in negotiating oncology drug prices in Italy, hig…
- Cytological Specimens in the Molecular Era of Metastatic Melanoma — This whitepaper discusses the role of cytological specimens in diagnosing metastatic melanoma and th…